
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO SECTION 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File Number: 001-40310

INNOVIZ TECHNOLOGIES LTD.
(Translation of registrant's name into English)

Innoviz Technologies Campus
5 Uri Ariav Street, Bldg. C
Nitzba 300, Rosh HaAin, Israel
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Innoviz Technologies Ltd. (the “Company”) hereby furnishes the following documents as exhibits 99.1 and 99.2:

Exhibit No.	Description
99.1	Company’s Interim Unaudited Consolidated Financial Statements as of September 30, 2025 and for the Nine Months ended September 30, 2025 and September 30, 2024
99.2	Operating and Financial Review and Prospects

This Report on Form 6-K and related exhibits are incorporated by reference into the Company’s registration statements on Form F-3 (File Nos. 333-267646 and 333-289554) and Form S-8 (File Nos.333-255511, 333-265169, 333-270416, 333-277852 and 333-285758), and shall be a part thereof from the date on which this Form 6-K is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Innoviz Technologies Ltd.

By: /s/ Eldar Cegla

Name: Eldar Cegla

Title: Chief Financial Officer

Date: November 12, 2025

INNOVIZ TECHNOLOGIES LTD. AND ITS SUBSIDIARIES

INTERIM CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 30, 2025

UNAUDITED

INDEX

	<u>Page</u>
<u>Interim Consolidated Balance Sheets</u>	F-2 - F-3
<u>Interim Consolidated Statements of Operations</u>	F-4
<u>Interim Statements of Changes in Shareholders' Equity</u>	F-5
<u>Interim Consolidated Statements of Cash Flows</u>	F-6 - F-7
<u>Notes to Interim Consolidated Financial Statements</u>	F-8 - F-16

INNOVIZ TECHNOLOGIES LTD. AND ITS SUBSIDIARIES

INTERIM CONSOLIDATED BALANCE SHEETS (UNAUDITED)

U.S. dollars in thousands (except share and per share data)

	<u>September 30,</u> <u>2025</u>	<u>December 31,</u> <u>2024</u>
ASSETS		
CURRENT ASSETS:		
Cash and cash equivalents	\$ 7,886	\$ 25,365
Short-term restricted cash	16	16
Bank deposits	57,120	30,628
Marketable securities	9,372	11,955
Trade receivables, net	19,811	6,043
Inventory	2,968	1,905
Prepaid expenses and other current assets	5,018	6,707
<u>Total current assets</u>	<u>102,191</u>	<u>82,619</u>
LONG-TERM ASSETS:		
Restricted deposits	3,106	2,725
Property and equipment, net	19,892	23,432
Operating lease right-of-use assets, net	25,785	23,194
Other long-term assets	89	79
<u>Total long-term assets</u>	<u>48,872</u>	<u>49,430</u>
Total assets	<u>\$ 151,063</u>	<u>\$ 132,049</u>

The accompanying notes are an integral part of the interim consolidated financial statements.

INNOVIZ TECHNOLOGIES LTD. AND ITS SUBSIDIARIES

INTERIM CONSOLIDATED BALANCE SHEETS (UNAUDITED)

U.S. dollars in thousands (except share and per share data)

	<u>September 30,</u> <u>2025</u>	<u>December 31,</u> <u>2024</u>
LIABILITIES AND SHAREHOLDERS' EQUITY		
CURRENT LIABILITIES:		
Trade payables	\$ 9,232	\$ 8,813
Deferred revenues	2,136	274
Employees and payroll accruals	9,661	8,722
Accrued expenses and other current liabilities	5,326	5,631
Operating lease liabilities	5,745	4,330
<u>Total current liabilities</u>	<u>32,100</u>	<u>27,770</u>
LONG-TERM LIABILITIES:		
Operating lease liabilities	29,253	25,264
Warrants liability	43	86
<u>Total long-term liabilities</u>	<u>29,296</u>	<u>25,350</u>
SHAREHOLDERS' EQUITY:		
Ordinary shares of no-par value: Authorized: 500,000,000 shares as of September 30, 2025 and December 31, 2024; Issued and outstanding: 208,542,156 and 169,397,030 shares as of September 30, 2025 and December 31, 2024, respectively	-	-
Additional paid-in capital	866,252	808,974
Accumulated deficit	(776,585)	(730,045)
<u>Total shareholders' equity</u>	<u>89,667</u>	<u>78,929</u>
Total liabilities and shareholders' equity	<u>\$ 151,063</u>	<u>\$ 132,049</u>

The accompanying notes are an integral part of the interim consolidated financial statements.

INNOVIZ TECHNOLOGIES LTD. AND ITS SUBSIDIARIES

INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

U.S. dollars in thousands (except share and per share data)

	Nine Months Ended September 30,	
	2025	2024
Revenues	\$ 42,415	\$ 18,241
Cost of revenues	(31,575)	(19,941)
Gross profit (loss)	10,840	(1,700)
Operating expenses:		
Research and development	40,354	60,328
Sales and marketing	4,183	5,752
General and administrative	13,109	14,889
Total operating expenses	57,646	80,969
Operating loss	(46,806)	(82,669)
Financial income, net	385	6,637
Loss before taxes on income	(46,421)	(76,032)
Taxes on income	(119)	(129)
Net loss	\$ (46,540)	\$ (76,161)
Basic and diluted net loss per ordinary share	\$ (0.24)	\$ (0.46)
Weighted average number of ordinary shares used in computing basic and diluted net loss per ordinary share	196,237,671	166,657,624

The accompanying notes are an integral part of the interim consolidated financial statements.

INNOVIZ TECHNOLOGIES LTD. AND ITS SUBSIDIARIES

INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (UNAUDITED)

U.S. dollars in thousands (except share and per share data)

	Ordinary Shares		Additional Paid-in Capital	Accumulated Deficit	Total Shareholders' Equity
	Number	Amount			
Balance as of January 1, 2024	165,387,098	\$ -	\$ 788,577	\$ (635,288)	\$ 153,289
Exercise of shares options	316,256	-	169	-	169
Vesting of RSUs	2,667,816	-	-	-	-
Share-based compensation	-	-	15,331	-	15,331
Net Loss	-	-	-	(76,161)	(76,161)
Balance as of September 30, 2024	168,371,170	\$ -	\$ 804,077	\$ (711,449)	\$ 92,628
Balance as of January 1, 2025	169,397,030	\$ -	\$ 808,974	\$ (730,045)	\$ 78,929
Issuance of ordinary shares and warrants, net of issuance costs	28,776,978	-	37,289	-	37,289
Issuance of ordinary shares, net of issuance costs	4,894,936	-	7,927	-	7,927
Exercise of shares options	1,008,454	-	710	-	710
Vesting of RSUs	4,464,758	-	-	-	-
Share-based compensation	-	-	11,352	-	11,352
Net Loss	-	-	-	(46,540)	(46,540)
Balance as of September 30, 2025	208,542,156	\$ -	\$ 866,252	\$ (776,585)	\$ 89,667

The accompanying notes are an integral part of the interim consolidated financial statements.

INNOVIZ TECHNOLOGIES LTD. AND ITS SUBSIDIARIES

INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS(UNAUDITED)

U.S. dollars in thousands (except share and per share data)

	Nine Months Ended September 30,	
	2025	2024
<u>Cash flows from operating activities:</u>		
Net loss	\$ (46,540)	\$ (76,161)
Adjustments required to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	4,076	6,194
Remeasurement of warrants liability	(43)	(176)
Change in accrued interest on bank deposits	(931)	891
Change in marketable securities	(130)	(450)
Share-based compensation	11,850	15,866
Foreign exchange gain, net	(1,326)	(134)
Change in prepaid expenses and other assets	1,181	2,914
Change in trade receivables, net	(13,768)	3,856
Change in inventory	616	641
Change in operating lease assets and liabilities, net	2,813	(992)
Change in trade payables	858	(1,703)
Change in accrued expenses and other liabilities	(244)	(3,428)
Change in employees and payroll accruals	939	241
Change in deferred revenues	1,862	(6,671)
Net cash used in operating activities	(38,787)	(59,112)
<u>Cash flows from investing activities:</u>		
Purchase of property and equipment	(3,210)	(3,221)
Proceeds from sales of property and equipment	3	-
Investment in bank deposits	(77,900)	(26,700)
Withdrawal of bank deposits	52,350	88,600
Investment in restricted deposits	(120)	(122)
Investment in marketable securities	(29,898)	(33,457)
Proceeds from sales and maturities of marketable securities	32,611	35,290
Net cash provided by (used in) investing activities	\$ (26,164)	\$ 60,390

The accompanying notes are an integral part of the interim consolidated financial statements.

INNOVIZ TECHNOLOGIES LTD. AND ITS SUBSIDIARIES

INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

U.S. dollars in thousands (except share and per share data)

	Nine Months Ended September 30,	
	2025	2024
<u>Cash flows from financing activities:</u>		
Issuance of ordinary shares and warrants, net of issuance costs	37,289	-
Issuance of ordinary shares, net of paid issuance costs	8,419	-
Proceeds from exercise of options	710	169
Net cash provided by financing activities	46,418	169
Effect of exchange rate changes on cash, cash equivalents and restricted cash	1,054	182
Increase (decrease) in cash, cash equivalents and restricted cash	(17,479)	1,629
Cash, cash equivalents and restricted cash at the beginning of the period	25,381	26,336
Cash, cash equivalents and restricted cash at the end of the period	\$ 7,902	\$ 27,965
<u>Supplementary disclosure of cash flows activities:</u>		
(1) Cash paid during the period for:		
Income taxes	\$ 248	\$ 180
(2) Non-cash transactions:		
Purchase of property and equipment	\$ 543	\$ 1,063
Reclassification from property and equipment, net to inventory	\$ 1,679	\$ -
Exercise of options	\$ 40	\$ -
Right-of-use assets recognized with corresponding lease liabilities due to lease modification	\$ 4,541	\$ -
Sale of machinery (see Note 4)	\$ 2,915	\$ -
Issuance costs to be paid	\$ 492	\$ -
(3) Cash, cash equivalents and restricted cash at the end of the period:		
Cash and cash equivalents	\$ 7,886	\$ 27,949
Short-term restricted cash	16	16
	\$ 7,902	\$ 27,965

The accompanying notes are an integral part of the interim consolidated financial statements.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands (except share and per share data)

NOTE 1:- GENERAL

- a. Innoviz Technologies Ltd. and its subsidiaries (the “Company” or “Innoviz”) is a Tier-1 direct supplier of high-performance, automotive grade LiDAR sensor platforms and complementary solutions that feature technological breakthroughs across core components and bring enhanced vision and superior performance to enable safe autonomous driving at a mass scale. The Company provides a comprehensive solution for OEMs (original equipment manufacturers) and Tier-1 partners that are developing and marketing autonomous driving vehicles to the passenger car and other relevant markets, such as robotaxis, shuttles, delivery vehicles and trucks.
- b. The Company was incorporated on January 18, 2016, under the laws of the state of Israel.
- c. On December 10, 2020, the Company entered into definitive agreements in connection with a merger (the “Transactions”) with Collective Growth Corporation (“Collective Growth”), a special purpose acquisition company, that resulted in Collective Growth becoming a wholly owned subsidiary of the Company upon the consummation of the Transactions on April 5, 2021 (the “Closing Date”).

The Company's ordinary shares and warrants were listed on the Nasdaq Stock Market LLC under the trading symbols “INVZ” and “INVZW,” respectively, on April 5, 2021.

- d. As of September 30, 2025 the Company's principal source of liquidity includes its cash and cash equivalents in the amount of \$7,886, bank deposits in the amount of \$57,120 and marketable securities in the amount of \$9,372, which is sufficient to finance its business plan for at least the next 12 months from the date these interim consolidated financial statements are issued. As the Company achieves further commercial success, it may need to obtain additional funding to support its continuing operations. If the Company is unable to obtain capital when and if needed, it may need to reduce or eliminate some of its research and development programs.
- e. In October 2023, Israel was attacked by a terrorist organization and entered a state of war. In October 2025, the sides agreed to a ceasefire, although there is no assurance that this agreement will be upheld. As of the date of these interim consolidated financial statements, the potential for renewed hostilities and any future escalation are difficult to predict, as such are the economic implications of the conflict on the Company's operational and financial performance. The Company considered the impact of the war and determined that there were no material adverse impacts on the interim consolidated financial statements, including related significant estimates made by management, for the period ended September 30, 2025.

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES

- a. Interim financial statements

The accompanying interim consolidated balance sheet as of September 30, 2025, the interim consolidated statements of operations and the interim consolidated statements of cash flows for the nine months ended September 30, 2025 and 2024, as well as the interim statement of changes in shareholders' equity for the nine months ended September 30, 2025 and 2024, are unaudited. These unaudited interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting.

U.S. dollars in thousands (except share and per share data)

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES (Cont.)

In management's opinion, the unaudited interim consolidated financial statements include all adjustments of a normal recurring nature necessary for the fair statement of the Company's financial position as of September 30, 2025, as well as its results of operations and cash flows for the nine months ended September 30, 2025 and 2024. The results of operations for the nine months ended September 30, 2025 are not necessarily indicative of the results to be expected for the year ending December 31, 2025 or for other interim periods or for future years.

b. Significant accounting policies

The accompanying unaudited interim consolidated financial statements should be read in conjunction with the Company's Annual Report on Form 20-F for the fiscal year ended December 31, 2024 (the "2024 Annual Report") filed with the SEC on March 12, 2025.

There have been no changes to the significant accounting policies described in the 2024 Annual Report that have had a material impact on the unaudited interim consolidated financial statements and related notes.

c. Use of estimates:

The preparation of interim consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the interim consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.

Significant items subject to such estimates and assumptions include inventory reserves and useful lives of property, plant, and equipment. The Company bases these estimates on historical and anticipated results, trends and various other assumptions that it believes are reasonable under the circumstances, including assumptions as to future events. Actual results could differ from those estimates.

d. Concentration of credit risk:

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, trade receivables, marketable securities, bank deposits and restricted deposits.

The majority of the Company's cash and cash equivalents and short-term bank deposits are invested with major banks in Israel. The Company believes that the financial institutions that hold the Company's cash deposits are financially sound and, accordingly, bear minimal risk.

Trade receivables of the Company are mainly derived from customers located globally. The Company mitigates its credit risks by performing credit evaluations of its customers' financial conditions and requires customer advance payments in certain circumstances. The Company generally does not require collateral.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands (except share and per share data)

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES (Cont.)

The Company invests in marketable securities with an average credit rating of “A” and a maturity of up to three years. The Company’s investment policy is not to invest more than 5% of its investment portfolio in a single security at time of purchase.

e. Recently issued accounting pronouncement not yet adopted:

1. In July 2025, the FASB issued ASU 2025-05, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. The ASU introduces a practical expedient for the application of the current expected credit loss (“CECL”) model to current accounts receivable and contract assets. The ASU is effective for fiscal years beginning after December 15, 2025, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the effect that ASU 2025-05 will have on its consolidated financial statements and related disclosures.
2. In September 2025, the FASB issued ASU 2025-06, Intangibles, Goodwill and Other Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software. The ASU removes all references to software development stages throughout ASC 350-40. Therefore, under the ASU, an entity will be required to start capitalizing software costs when management has authorized and committed to funding the software project, and it is probable that the project will be completed and the software will be used to perform the intended function. The ASU is effective for fiscal years beginning after December 15, 2027, and interim periods within those fiscal years. The ASU allows adoption either on a prospective basis, a modified prospective approach or a retrospective approach. The Company is currently evaluating the effects that ASU 2025-06 will have on its consolidated financial statements and related disclosures.

NOTE 3:- INVENTORY

Inventory is comprised of the following:

	<u>September 30,</u> <u>2025</u>	<u>December 31,</u> <u>2024</u>
Raw materials	\$ 1,929	\$ 837
Work in process	948	264
Finished goods	<u>91</u>	<u>804</u>
	<u>\$ 2,968</u>	<u>\$ 1,905</u>

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands (except share and per share data)

NOTE 4:- REVENUE RECOGNITION

During the nine months ended September 30, 2025 and 2024, the Company recognized revenue at a point in time for LiDAR sensors and critical components, after transferring the control of the goods to the customer of \$4,384 and \$4,386, respectively.

During the nine months ended September 30, 2025 and 2024, the Company recognized revenue at a point in time for application engineering services, after receiving customer acceptance of \$29,882 and \$13,855, respectively.

In June 2025 the Company entered into a contract with a customer for the sale of machinery (including subsequent adjustments to the machinery) for \$0,000. During the nine months ended September 30, 2025, the Company recognized revenue at a point in time from the sale of machinery, after transferring the control of the machinery to the customer of \$7,156. In addition, during the nine months ended September 30, 2025, the Company recognized revenue over time from the subsequent adjustments to the machinery of \$993.

Deferred Revenues

During the nine months ended September 30, 2025, the Company recognized \$207 that was included in deferred revenues balance at December 31, 2024.

Remaining Performance Obligation

The Company's remaining performance obligations are comprised of application engineering services revenues not yet rendered. As of September 30, 2025, the aggregate amount of the transaction price allocated to remaining performance obligations was \$12,888 (out of which none is recorded as deferred revenues), which the Company expects to recognize as revenues within the next 12 months.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands (except share and per share data)

NOTE 5:- FAIR VALUE MEASUREMENTS

The below tables set forth the Company's assets and liabilities that were measured at fair value as of September 30, 2025 and December 31, 2024 by level within the fair value hierarchy.

	September 30, 2025			
	Level 1	Level 2	Level 3	Total
Assets:				
Marketable securities	\$ -	\$ 9,372	\$ -	\$ 9,372
Total financial assets	\$ -	\$ 9,372	\$ -	\$ 9,372
Liabilities:				
Warrants (1)	\$ -	\$ -	\$ 43	\$ 43
Total financial liabilities	\$ -	\$ -	\$ 43	\$ 43

	December 31, 2024			
	Level 1	Level 2	Level 3	Total
Assets:				
Marketable securities	\$ -	\$ 11,955	\$ -	\$ 11,955
Total financial assets	\$ -	\$ 11,955	\$ -	\$ 11,955
Liabilities:				
Warrants (1)	\$ -	\$ -	\$ 86	\$ 86
Total financial liabilities	\$ -	\$ -	\$ 86	\$ 86

- (1) As part of the Transactions (see Note 1c), the Company assumed a derivative warrants liability related to previously issued private placement warrants in connection with Collective Growth's initial public offering. The Company utilizes a Black-Scholes option pricing model to estimate the fair value of the private placement warrants which is considered a Level 3 fair value measurement. The warrants are measured at each reporting period, with changes in fair value recognized in financing income, net.

The change in the fair value of the derivative private warrants liability is summarized as follows:

	Nine Months Ended September 30,	
	2025	2024
Balance as of January 1	\$ 86	\$ 240
Change in fair value of warrants liability	(43)	(176)
Balance as of September 30	\$ 43	\$ 64

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands (except share and per share data)

NOTE 6:- COMMITMENTS AND CONTINGENCIES

Legal proceedings:

On March 28, 2024, a putative class action lawsuit was filed in the Delaware Court of Chancery against several former officers and directors of Collective Growth (the “Defendants”) which relates to events preceding the Transactions. Under the Transactions agreements, the Company may be required to honor all rights to indemnification or exculpation existing in favor of the directors and officers of Collective Growth, as were in effect prior to the Closing Date, solely with respect to any matters occurring on or prior to the Closing Date. The lawsuit generally alleges that the Defendants impaired Collective Growth’s public stockholders’ ability to exercise their redemption on an informed basis in connection with the Transactions, by failing to disclose material information in the proxy statement concerning the Defendants’ interests relating to the Transactions and the net cash per share that Collective Growth could contribute to the Transactions. The lawsuit asserts claims for breach of fiduciary duty and unjust enrichment.

On June 21, 2024, the Defendants’ legal counsel filed a motion to dismiss. On August 9, 2024, an amended complaint was filed, and in response, on August 23, 2024, the Defendants’ legal counsel submitted an amended motion to dismiss. Briefing on the amended motion to dismiss was completed on December 20, 2024. On October 1, 2025, the plaintiff submitted a letter to the court, enclosing supplemental authorities on issues relating to laches, i.e., the time to file an equitable claim. Oral argument on the Defendants’ motion to dismiss was held on October 27, 2025. After the oral argument, the plaintiff submitted a letter to the court to request permission to file a supplemental brief to address comments relating to laches made by the court during the hearing. The court has taken Defendants’ motion to dismiss under advisement and has not yet ruled on the motion.

The Defendants intend to vigorously defend against the claim.

As of the date hereof, the Company, with advice of its legal counsel, is unable to estimate the likelihood of an outcome, favorable or unfavorable to the Company. Hence, an estimated liability has not been recorded in the interim consolidated financial statements.

Other than noted above, the Company is currently not part, as plaintiff or defendant, to any legal proceedings that, individually or in the aggregate, are expected by the Company to have a material effect on the Company’s business, financial position, results of operations or cash flows.

NOTE 7: - EQUITY ISSUANCE

- a. On February 12, 2025, the Company issued a total of 28,776,978 ordinary shares of no par value and 23,021,582 warrants to purchase one ordinary share, at an offering price of \$1.39 per unit (each unit consisting of one ordinary share and eight tenths of a warrant), for a total consideration of \$7,289, net of placement agent fees and other issuance costs of \$2,711. The warrants are immediately exercisable at \$1.69 per share and will expire five years from the date of issuance. The warrants were classified as equity in the Company’s interim consolidated financial statements.

U.S. dollars in thousands (except share and per share data)

NOTE 7: - EQUITY ISSUANCE (Cont.)

- b. On August 13, 2025, the Company entered into an Open Market Sale Agreement (the “Sales Agreement”) with a sales agent. In accordance with the terms of the Sales Agreement, the Company may offer and sell its ordinary shares from time to time through the sales agent, having an aggregate offering price of up to \$75,000. The Sales Agreement is subject to certain limitations on the number of shares to be sold in any single day and any minimum price below sales may not be made.
- As of September 30, 2025, the Company issued 4,894,936 ordinary shares of no par value under the Sales Agreement for a total consideration of \$7,927, net of sales agent fees and other issuance costs of \$798.

NOTE 8:- BASIC AND DILUTED NET LOSS PER SHARE

The following table sets forth the computation of the net loss per share for the period presented:

	Nine Months Ended September 30,	
	2025	2024
Numerator:		
Net Loss	\$ (46,540)	\$ (76,161)
Denominator:		
	196,237,671	166,657,624

- The following potential ordinary shares have been excluded from the calculation of diluted net loss per share for the period presented due to their anti-dilutive effect:
- a. 39,252,723 warrants, 29,600,867 outstanding options to purchase ordinary shares and unvested RSUs as of September 30, 2025.
- b. 16,231,141 warrants, 2,402,178 sponsors earnout shares, 28,937,629 outstanding options to purchase ordinary shares and unvested RSUs as of September 30, 2024.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands (except share and per share data)

NOTE 9:- SEGMENT INFORMATION

a. Segment information:

	Nine Months Ended September 30,	
	2025	2024
Revenues from external customers	\$ 42,415	\$ 18,241
Less:		
Cost of revenues	31,575	19,941
Research and development expenses	40,354	60,328
Sales and marketing expenses	4,183	5,752
General and administrative expenses	13,109	14,889
Financial income, net	(385)	(6,637)
Taxes on income	119	129
Segment loss	\$ 46,540	\$ 76,161
Other segment disclosures:		
Depreciation and amortization expenses	\$ 4,076	\$ 6,194
Share-based compensation expenses	\$ 11,850	\$ 15,866
Interest income	\$ 2,625	\$ 4,326
Expenditures for segment assets	\$ 3,210	\$ 3,221
	September 30,	December 31,
	2025	2024
Assets:		
Segment assets	\$ 151,063	\$ 132,049

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands (except share and per share data)

NOTE 9:- SEGMENT INFORMATION (Cont.)

b. Geographic information:

Following is a summary of revenues by geographic areas. Revenues attributed to geographic areas, based on the location where the customers accept delivery of the products and services:

	Nine Months Ended September 30,	
	2025	2024
Europe, Middle East and Africa (*)	\$ 37,203	\$ 16,229
Americas (**)	3,730	916
Israel	1,399	969
Asia Pacific	83	127
	<u>\$ 42,415</u>	<u>\$ 18,241</u>

(*) Includes revenues from Germany only.

(**) Includes revenues from United States in the amount of \$3,712 and \$916 for the nine months ended September 30, 2025 and 2024, respectively.

c. Concentration of credit risk from major customers:

As of September 30, 2025, Customer A and Customer B accounted for approximately 82% and 16% of the Company's trade receivables.

As of December 31, 2024, Customer A and Customer C accounted for approximately 73% and 23% of the Company's trade receivables, respectively.

OPERATING AND FINANCIAL REVIEW AND PROSPECTS

You should read the following discussion and analysis of our financial condition and results of operations together with (i) our unaudited interim consolidated financial statements as of and for the nine months ended September 30, 2025, included as Exhibit 99.1 to this Report on Form 6-K (this “Report”), (ii) our audited consolidated financial statements and other financial information as of and for the year ended December 31, 2024 appearing in our Annual Report on Form 20-F for the year ended December 31, 2024 (our “Annual Report”) and (iii) Item 5 — “Operating and Financial Review and Prospects” of our Annual Report. Some of the information contained in this discussion and analysis, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the section entitled “Cautionary Statement Regarding Forward-Looking Statement” and in the section entitled Item 3.D. “Risk Factors” of our Annual Report, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Unless otherwise designated, the terms “we”, “us”, “our”, “Innoviz”, “the Company” and “our company” refer to Innoviz Technologies Ltd.

All references in this Report to “Israeli currency” and “ILS” refer to Israeli New Shekels, and the terms “dollar,” “USD” or “\$” refer to U.S. dollars.

Forward-Looking Statements

Statements in this Report may constitute “forward-looking statements” within the meaning of the United States federal securities laws. These forward-looking statements can generally be identified as such because the context of the statement will include words such as “may,” “might,” “will,” “could,” “would,” “intends,” “plans,” “believes,” “anticipates,” “expects,” “seeks,” “estimates,” “predicts,” “potential,” “continue,” “contemplate” or “opportunity,” the negative of these words or words of similar import. Similarly, statements that describe our business outlook or future economic performance, anticipated revenues, expenses or other financial items, introductions and advancements in development of products, and plans and objectives related thereto, and statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are also forward-looking statements. Forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those stated in such statements. Factors that could cause or contribute to such differences include, but are not limited to, those set forth in Item 3.D. “Risk Factors” in our Annual Report, as well as those discussed elsewhere in our Annual Report and in our other filings with the U.S. Securities and Exchange Commission (the “SEC”).

Company Overview

We are a leading Tier-1 direct supplier of high-performance, automotive grade LiDAR sensor platforms and complementary software stack that feature technological breakthroughs across core components and bring enhanced vision and superior performance to enable safe autonomous driving at a mass scale. We believe that we provide a comprehensive solution for OEMs (original equipment manufacturers) and Tier-1 partners that are developing and marketing autonomous driving vehicles to the passenger car and other relevant markets, such as robotaxis, shuttles, delivery vehicles and trucks.

We were founded in 2016. From our founding, our culture drew from our core values of solving sophisticated technological problems through creativity and agile thinking. We have relied on these values to address the needs of autonomous vehicles in a manner that strikes the desired balance between performance and cost. We created a new type of LiDAR sensor from the chip-level up, including a suite of powerful and sophisticated software applications for high-performance computer vision to allow superior perception. In 2018, we achieved a design win to power BMW’s Level 3 autonomous platform, a program which reached maturity during 2024 and with vehicles already being sold with our LiDARs and complementary software stack.

Since 2021, we have funded the development of two production path programs: the InnovizOne and InnovizTwo LiDAR sensor platforms and complementary software stacks. With the InnovizOne program transitioned from the development phase into full series production in 2024, we eliminated duplicative cost structures and reduced spending on InnovizOne development, while reinvesting a portion of the savings into the InnovizTwo sensor platform and complementary software stack. All quoting and bidding activity in our request for information and request for quotation pipeline is now focused on the InnovizTwo platform.

During 2022, we made the strategic decision to become a Tier-1 supplier of LiDAR and complementary software stack to the automotive industry. This decision allows us to have direct technical discussions with end customers and to improve pricing to automotive OEMs with the goal of continuing to strengthen our position in the automotive market. This strategic decision has played a significant role in our subsequent major OEM program wins, as discussed below.

In 2022, following more than two years of extensive diligence and qualification, we were selected by Volkswagen as its direct LiDAR supplier for automated vehicles within the Volkswagen brands with our InnovizTwo next generation high-performance automotive-grade LiDAR sensor platform, and in 2023, we announced that Volkswagen aims to expand its use of our InnovizTwo LiDAR to its existing light commercial vehicle program, the I.D Buzz.

In 2024, we announced that Mobileye Vision Technologies Ltd. (“Mobileye”) will use the InnovizTwo Long-Range and the new InnovizTwo Short- to Mid-Range LiDARs for the Mobileye Drive™ platform. The new InnovizTwo Short- to Mid-Range leverages InnovizTwo Long-Range’s maturity and is designed to meet the requirements for light commercial vehicles, shuttles, robotaxis, and can be customized to suit a wide array of vehicular design and functionality requirements. We believe that the combination of our LiDARs and Mobileye’s platform is critical to enabling comprehensive sensing capabilities for navigating complex urban environments and enhancing the overall safety and reliability of autonomous driving systems, and that this partnership showcases the flexibility of our LiDARs to work across a variety of vehicle platforms to further testing and deployment of autonomous vehicles. Our partners are leaders in deploying new technologies into the automotive industry. We believe that our close cooperation with these partners and OEMs positions us well to make Level 3 and Level 4 autonomous driving a commercial reality.

The sustained cooperation with our customers provides our engineers and other research and development personnel with a valuable competitive edge. These engineers and other research and development personnel have been meticulously trained to design, operate and verify our many ground-breaking innovations in accordance and in compliance with the rigorous ISO26262 standard for functional safety in the automotive industry, and the IATF 16949:2016 certification for quality management in the automotive industry. Compliance with these and other standards has been enforced by regular ongoing audits of Innoviz and rigorous testing by our key suppliers, existing customers and prospective customers that thoroughly review the performance of various elements of our operations. As a result, our products have been constructed from the bottom up with hardware and software technology that meets the most stringent automotive safety, quality, environmental, manufacturing, and other standards.

Our innovation has produced LiDAR solutions that deliver market leading performance and that meet the demanding safety requirements for Level 2+ through Level 5 autonomous vehicles at price points suitable for mass produced passenger vehicles.

Our robust software suite enables our ~905nm wavelength laser-based LiDAR architecture to be easily leveraged to provide compelling solutions for Level 2+ through Level 4 (and Level 5 when applicable), using both our long- and short- to medium-range LiDARs. Our integrated custom design of advanced hardware and software components, which leverages the multidisciplinary expertise and experience of our team, enables us to provide autonomous solutions that we believe will accelerate widespread adoption across automakers at serial production scale. This means that we are positioned to penetrate the current market, which is focused primarily on Level 2+, Level 3 and Level 4 production, and to continue to capture and extend our market share to Level 5, as the market continues to mature.

In February 2025, we announced an optimization of our operations to extend our cash runway and accelerate progress towards profitability and free cash flow generation, resulting in a reduction in our employee headcount of approximately 9% during the first quarter of 2025.

We are currently expanding our third-party manufacturing capacity through contract manufacturers to meet an anticipated increase in customer demand for our products. As part of this effort, we selected Fabrinet (NYSE: FN), a leading provider of advanced optical packaging and precision optical, electro-mechanical, and electronic manufacturing services, as our manufacturing partner for the InnovizTwo LiDAR platform. In July 2025, we announced the shipment of the first InnovizTwo LiDAR units from Fabrinet’s high-volume production line. This collaboration is expected to enable Innoviz to ramp its InnovizTwo LiDARs to volume with a manufacturing partner that has automotive-grade facilities around the world, allowing for flexible and cost-effective production.

In response to the growing interest and demand for LiDAR technologies across a range of non-automotive sectors, in June 2025 we announced the launch of InnovizSMART Long-Range, a new high-performance LiDAR sensor designed specifically for “smart” applications, including security, mobility, aerial, robotics, and intelligent traffic management. With the maturation of our InnovizTwo LiDAR platform and expanding production capabilities through third-party capacity, we are expanding our focus to additional markets such as ITS, smart cities and other sectors that are seeking affordable, high-performing LiDAR solutions. Innoviz’s advanced offerings are well-positioned to address the evolving requirements of these industries, supporting a wide variety of new applications.

Recent Developments

Achieving ISO/IEC 17025:2017 certification for LiDAR Testing Laboratories

On September 30, 2025, we announced that our hardware qualification testing laboratories received ISO/IEC 17025:2017 certification, an internationally recognized standard that validates the competence of our testing and calibration laboratories.

Selection by a Major Commercial Vehicle OEM for Future Series Production of Level 4 Autonomous Trucks

On September 8, 2025, we announced that we have been selected as a future series production supplier by a major commercial vehicle OEM to supply advanced LiDAR units for SAE (Society of Automotive Engineers) Level 4 autonomous class-8 semi-trucks.

Open Market Sale AgreementSM with Jefferies

On August 13, 2025, we entered into an Open Market Sale AgreementSM (the “Sales Agreement”) with Jefferies LLC relating to the sale of our ordinary shares and filed a sales agreement prospectus together with a base prospectus on Form F-3 with the SEC. In accordance with the terms of the Sales Agreement, pursuant to the filed sales agreement prospectus, we may offer and sell our ordinary shares having an aggregate offering price of up to \$75,000,000 from time to time through or to Jefferies LLC, acting as sales agent and/or principal (the “ATM Program”). During the quarter ended September 30, 2025, we issued and sold 4,894,936 shares under the ATM program for net proceeds to the Company of approximately \$7.9 million.

Events in Israel

On October 9, 2025, Israel, Hamas, the United States and other countries in the region agreed to a framework for a ceasefire in Gaza between Israel and Hamas. It is unknown whether this ceasefire will endure, or if other conflicts in Gaza, Lebanon, Yemen, Iran, or in the broader region will reemerge or escalate in the future, as military activity and hostilities continue to exist at varying levels of intensity, and the situation remains volatile. At this time, we do not expect the current conflict (or other ongoing conflicts) to have a material impact on our financial and operational results; however, since these are events beyond our control, their continuation or cessation may affect our expectations. We continue to monitor political and military developments closely and examine the consequences for our operations, assets and financial and operational results.

A. Results of Operations

The results of operations presented below should be reviewed in conjunction with (i) our unaudited interim consolidated financial statements as of and for the nine months ended September 30, 2025, included in Exhibit 99.1 to this Report, (ii) our audited consolidated financial statements as of and for the year ended December 31, 2024 appearing in our Annual Report, and (iii) Item 5 - "Operating and Financial Review and Prospects" of our Annual Report. The following table sets forth our consolidated results of operations data for the periods presented:

	Nine Months Ended September 30,	
	2025	2024
	(In thousands, except share and per share data) (unaudited)	
Revenues	\$ 42,415	\$ 18,241
Cost of revenues	(31,575)	(19,941)
Gross profit (loss)	10,840	(1,700)
Operating expenses:		
Research and development	40,354	60,328
Sales and marketing	4,183	5,752
General and administrative	13,109	14,889
Total operating expenses	57,646	80,969
Operating loss	(46,806)	(82,669)
Financial income, net	385	6,637
Loss before taxes on income	(46,421)	(76,032)
Taxes on income	(119)	(129)
Net loss	\$ (46,540)	\$ (76,161)
Basic and diluted net loss per ordinary share	\$ (0.24)	\$ (0.46)
Weighted average number of ordinary shares used in computing basic and diluted net loss per ordinary share	196,237,671	166,657,624

Comparison of the Nine Months Ended September 30, 2025 and 2024

Revenues

	Nine Months Ended September 30,		Change	Change
	2025	2024	\$	%
	(In thousands)	(In thousands)	(In thousands)	
Revenues	\$ 42,415	\$ 18,241	\$ 24,174	133%

Revenues increased by approximately \$24.2 million, or 133%, to approximately \$42.4 million for the nine months ended September 30, 2025 from approximately \$18.2 million for the nine months ended September 30, 2024.

The increase in revenues was primarily due to increased sales of NRE (Non-Recurring Engineering services), which contributed approximately \$29.9 million during the nine months ended September 30, 2025 compared to approximately \$13.9 million in revenues during the nine months ended September 30, 2024, as well as the sale of machinery to a customer during the nine months ended September 30, 2025.

Cost of Revenues and Gross Margin

	Nine Months Ended September 30,		Change	Change
	2025	2024	\$	%
	(In thousands except percentages)	(In thousands except percentages)	(In thousands)	
Cost of revenues	\$ 31,575	\$ 19,941	\$ 11,634	58%
Gross margin	26%	(9)%		

Cost of revenues increased by approximately \$11.6 million, or 58%, to approximately \$31.6 million for the nine months ended September 30, 2025 from approximately \$19.9 million for the nine months ended September 30, 2024.

The increase in cost of revenues was primarily due to an increase in costs related to sales of NRE and costs related to sale of machinery to a customer, partially offset by decreased excess and obsolete inventory. Gross margin increased to approximately 26% for the nine months ended September 30, 2025 from approximately (9)% for the nine months ended September 30, 2024, primarily due to increased sales of NRE, the sale of machinery to a customer and decreased excess and obsolete inventory.

Operating Expenses

	Nine Months Ended September 30,		Change	Change
	2025	2024	\$	%
	(In thousands)	(In thousands)	(In thousands)	
Research and development	\$ 40,354	\$ 60,328	\$ (19,974)	(33)%
Sales and marketing	4,183	5,752	(1,569)	(27)%
General and administrative	13,109	14,889	(1,780)	(12)%
Total operating expenses	\$ 57,646	\$ 80,969	\$ (23,323)	(29)%

Research and Development

Research and development expenses decreased by approximately \$20.0 million, or 33%, to approximately \$40.4 million for the nine months ended September 30, 2025 from approximately \$60.3 million for the nine months ended September 30, 2024.

The decrease was primarily attributable to decreased payroll of approximately \$13.0 million (primarily related to allocation of direct costs related to sales of NRE and to a decrease in headcount), decreased stock-based compensation of approximately \$4.8 million and decreased materials purchases and prototype expenses of approximately \$1.1 million.

Sales and Marketing

Sales and marketing expenses decreased by approximately \$1.6 million, or 27%, to approximately \$4.2 million for the nine months ended September 30, 2025 from approximately \$5.8 million for the nine months ended September 30, 2024.

The decrease was primarily attributable to decreased payroll of \$0.9 million (primarily attributed to a decrease in headcount) and decreased stock-based compensation of \$0.4 million.

General and Administrative

General and administrative expenses decreased by approximately \$1.8 million, or 12%, to approximately \$13.1 million for the nine months ended September 30, 2025 from approximately \$14.9 million for the nine months ended September 30, 2024.

The decrease was primarily attributable to decreased legal consulting services of approximately \$1.0 million and decreased stock-based compensation of \$0.9 million.

Financial Income, net

	Nine Months Ended September 30,		Change	Change
	2025	2024	\$	%
	(In thousands)	(In thousands)	(In thousands)	
Financial income, net	\$ 385	\$ 6,637	\$ (6,252)	(94)%

Financial income, net was approximately \$0.4 million for the nine months ended September 30, 2025, compared to financial income, net of approximately \$6.6 million for the nine months ended September 30, 2024.

The decrease was primarily related to foreign currency exchange differences of approximately \$4.1 million (primarily due to differences arising from our ILS denominated lease liabilities under ASC 842), decreased bank deposits interest income of approximately \$1.7 million, decreased net gain related to marketable securities of approximately \$0.3 million and warrants liability revaluation of approximately \$0.1 million.

Quantitative and Qualitative Disclosures About Market Risk

We are exposed to a variety of risks, including foreign currency exchange fluctuations, changes in interest rates and inflation. We regularly assess currency, interest rate and inflation risks to minimize any adverse effects on our business as a result of those factors.

Foreign Currency Risk

Our financial results are reported in USD, and changes in the exchange rate between USD and local currencies in the countries in which we operate (primarily ILS) may affect the results of our operations. In the nine months ended September 30, 2025, all of our revenues were denominated in USD. The USD cost of our operations in countries other than the United States may be negatively influenced by devaluation of the USD against other currencies.

During the nine months ended September 30, 2025, the value of the USD devaluated against the value of the ILS by approximately 9.4%. Our most significant foreign currency exposures are related to our operations in Israel. We hedge our anticipated exposure by exchanging USD into ILS in amounts sufficient to fund up to three months of operations and monitoring foreign currency exchange rates over time.

Interest Rate Risk

Our investment strategy is to achieve a return that will allow us to preserve capital and meet our liquidity requirements. We invest in bank deposits and marketable securities, primarily in USD.

Our cash and cash equivalents are exposed to market risk related to changes in interest rates, which is affected by changes in the general level of the Bank of Israel interest rates and United States Federal Reserve interest rates. Due to the short-term nature and the low-risk profile of our interest-bearing accounts, an immediate 10% change in interest rates would not have a material effect on the fair market value of our cash and cash equivalents, bank deposits and restricted deposits or on our financial position or results of operations.

Our investments in marketable securities are primarily in securities with an average credit rating of “A” and a maturity of up to three years. We do not intend to invest more than 5% of our investment portfolio in a single security at time of purchase.

Other Market Risks

We do not believe that inflation had a material effect on our business, financial conditions or results of operations during the nine months ended September 30, 2025 and 2024.

B. Liquidity and Capital Resources

Sources of Liquidity

During the nine months ended September 30, 2025 and 2024, we funded our operations primarily from the approximately \$370 million in proceeds we received in connection with our business combination with Collective Growth Corporation (completed in April 2021), the approximately \$61.4 million in net proceeds we received from our August 2023 underwritten equity offering, the approximately \$37.3 million in net proceeds we received from our February 2025 registered direct offering and the revenues generated from the sale of goods and services.

As of September 30, 2025, we had approximately \$74.4 million in cash and cash equivalents, short term bank deposits, short term restricted cash and marketable securities. Cash equivalents and marketable securities are invested in accordance with our investment policy.

Cash Flows Summary

The following table summarizes our cash flows for the periods presented:

	Nine Months Ended September 30,	
	2025	2024
	(In thousands)	(In thousands)
Net cash used in operating activities	\$ (38,787)	\$ (59,112)
Net cash provided by (used in) investing activities	(26,164)	60,390
Net cash provided by financing activities	46,418	169
Effect of exchange rate changes on cash, cash equivalents and restricted cash	1,054	182
Increase (decrease) in cash, cash equivalents and restricted cash	<u>\$ (17,479)</u>	<u>\$ 1,629</u>

Operating Activities

During the nine months ended September 30, 2025, operating activities used approximately \$38.8 million. The primary factors affecting operating cash flows during the nine months ended September 30, 2025, were the net loss of approximately \$46.5 million, impacted by non-cash charges of approximately \$7.7 million consisting of stock-based compensation of approximately \$11.9 million, depreciation and amortization of approximately \$4.1 million and an increase in working capital of approximately \$(8.3) million.

During the nine months ended September 30, 2024, operating activities used approximately \$59.1 million. The primary factors affecting operating cash flows during the nine months ended September 30, 2024, were the net loss of approximately \$76.2 million, impacted by non-cash charges of approximately \$17.1 million consisting of stock-based compensation of approximately \$15.9 million, depreciation and amortization of approximately \$6.2 million and an increase in working capital of approximately \$(5.0) million.

Investing Activities

During the nine months ended September 30, 2025, cash used in investing activities was approximately \$26.2 million, which primarily resulted from investment in bank deposits of approximately \$77.9 million, investment in marketable securities of approximately \$29.9 million and purchase of property and equipment of approximately \$3.2 million, partially offset by withdrawal of bank deposits of approximately \$52.4 million and proceeds from sales of marketable securities of approximately \$32.6 million.

During the nine months ended September 30, 2024, cash provided by investing activities was approximately \$60.4 million, which primarily resulted from withdrawal of bank deposits of approximately \$88.6 million and proceeds from sales and maturities of marketable securities of approximately \$35.3 million, partially offset by investment in marketable securities of approximately \$33.5 million, investment in bank deposits of approximately \$26.7 million and purchase of property and equipment of approximately \$3.2 million.

Financing Activities

During the nine months ended September 30, 2025, cash provided by financing activities was approximately \$46.4 million resulting from approximately \$37.3 million in proceeds from our registered direct offering, net of issuance costs, \$8.4 million in proceeds from the sale of our ordinary shares under the ATM Program, net of paid issuance costs and approximately \$0.7 million from the exercise of employee stock options.

During the nine months ended September 30, 2024, cash provided by financing activities was approximately \$0.2 million resulting from the exercise of employee stock options.

Funding Requirements

We expect to continue to invest substantially in our research and development activities and incur commercialization expenses related to product sales, marketing, manufacturing and distribution. As we achieve further commercial success, we may need to obtain additional funding to support our continuing operations. In addition, our financial stability is reviewed by existing and potential customers from time to time and we believe that a stronger cash position provides us additional time to execute our growth strategy and is perceived positively by existing and potential customers and may also provide us with higher grading in such customers' diligence processes. If we are unable to obtain capital when and if needed or on attractive terms, we could be forced to delay, reduce or eliminate some of our research and development programs or future commercialization efforts.

As of September 30, 2025, we had cash and cash equivalents, short term bank deposits, short term restricted cash and marketable securities of approximately \$74.4 million. We expect those funds to be sufficient to continue to execute our business plan for at least the next 12 months.

Additionally, we intend to fund our operations from revenues generated from the sale of goods and services, together with funds received under the registered direct offering, proceeds from our ATM Program and savings pursuant to optimization of our operations.

We also expect our losses to be similar or lower in future periods as we:

- anticipate additional inflows of NRE payments from various programs to balance some of our losses;
- expand production capabilities to produce our LiDAR solutions, and accordingly incur costs associated with outsourcing the production of our LiDAR solutions;
- expand our design, development, installation and servicing capabilities;
- continue to invest in research and development;
- increase our test and validation activities as part of our Tier-1 responsibilities;
- produce an inventory of our LiDAR solutions; and
- continue to invest in sales and marketing activities and develop our distribution infrastructure.

Because we will incur costs and expenses from these efforts before we receive incremental revenues with respect thereto, losses in future periods will be significant. In addition, we may find that these efforts are more expensive than we currently anticipate or that these efforts may not result in revenues, which would further increase our losses.

Off-Balance Sheet Arrangements

Our remaining performance obligations are comprised of application engineering services not yet rendered. As of September 30, 2025, the aggregate amount of the transaction price allocated to remaining performance obligations was approximately \$12.9 million, which we expect to recognize as revenues within the next 12 months.

Other than as set forth above, we have not entered into any off-balance sheet arrangements and do not have any holdings in variable interest entities.